Survivin as a Prognostic Factor for Osteosarcoma Patients

Eiji Osaka¹, Takashi Suzuki²,³, Shunzo Osaka¹, Yukihiro Yoshida¹, Hideyuki Sugita¹, Satoru Asami², Keiichi Tabata², Akihiro Hemmi¹, Masahiko Sugitani¹, Norimichi Nemoto⁴ and Junnosuke Ryu¹

¹Department of Orthopaedic Surgery, Nihon University School of Medicine, ²College of Pharmacy, Nihon University, ³Department of Pediatrics, Nihon University School of Medicine and ⁴Department of Pathology, Nihon University School of Medicine

Received February 14, 2006; accepted April 25, 2006; published online May 26, 2006

Purpose: Survivin is one of the apoptosis inhibitor genes and is rarely expressed in adult tissues. However, survivin expression has been detected in various human cancers and correlations have been recognized between the level of expression of this gene in tumors and prognosis. In this study, we investigated the correlations between survivin mRNA expression in osteosarcoma tissues and clinicopathological parameters.

Methods: There were 22 osteosarcoma patients in our hospital with paraffin-embedded tissues which could be extracted from biopsy specimens. We used the RT-PCR method after extracting total RNA and conducted a densitometric analysis to determine the ratio of survivin relative to h-GAPDH as an internal marker.

Results: Expression of survivin mRNA was detected in all osteosarcoma samples. Patients with metastasis had high survivin mRNA levels in initial biopsy specimens (p < 0.01). Moreover, there was a statistically significant difference in survivin mRNA expression between patients with and without metastasis (p < 0.01).

Conclusion: We concluded that high levels of survivin mRNA expression suggest poor prognosis for osteosarcoma patients.

Key words: survivin, prognostic factor, osteosarcoma, paraffin-embedded tissue

I. Introduction

Osteosarcoma is associated with high morbidity rates in young adults and adolescents. It is an aggressive tumor which frequently metastasizes to the lung. Current treatment protocols for osteosarcoma include wide surgical resection of the primary lesion and multidrug chemotherapy [4, 19]. Clinically, prognosis is determined postoperatively by the response to chemotherapy and, in the past, by tumor size and wide surgical margin. These have long been the only useful prognostic factors for osteosarcoma patients.

Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is characterized by a unique structure. It contains only a single baculovirus inhibitor of apoptosis protein repeat (BIR) and lacks a carboxy terminal really interesting new gene (RING) finger domain. It also binds directly to both caspase-3 and caspase-7, thereby inhibiting apoptosis [5].

Moreover, survivin is abundantly expressed during fetal development but not in adult human tissues [3]. Survivin mRNA has been detected in various human malignant neoplasms, such as gastric cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, urinary bladder cancer, soft tissue sarcoma, neuroblastoma and osteosarcoma. Survivin has thus been thought to promote tumor progression [12–17, 20, 21, 25, 27].

In this study, we measured survivin expression levels in paraffin-embedded osteosarcoma tissues, and concluded that high survivin mRNA expression levels may serve as a prognostic factor for osteosarcoma patients.

Correspondence to: Eiji Osaka, M.D., Department of Orthopaedic Surgery, Nihon University School of Medicine, 30–1 Oyaguchikamachi, Itabashi-ku, Tokyo 173–8610, Japan.
E-mail: eosaka@med.nihon-u.ac.jp

© 2006 The Japan Society of Histochemistry and Cytochemistry
II. Material and Methods

Patients and tissue samples

Twenty-two tissue specimens, all obtained from osteosarcoma patients at the Department of Orthopaedic Surgery, Nihon University School of Medicine, during the period from 1992 to 2000, were embedded in paraffin. The patients were 14 males and eight females, with a mean age of 25 years (range 8 to 62 years). Twenty patients had Enneking’s stage IIB, and the remaining two stage IIIB [9]. The tumors were located on the distal femur in nine patients, proximal tibia in five patients, proximal fibula in one patient, proximal humerus in two patients, vertebrae in two patients and at other sites in three patients. The histological type of osteosarcoma was osteoblastic in 14 patients, chondroblastic in four patients and fibroblastic in four patients. Twenty-one patients underwent resection after the initial biopsy, but one received wide resection as the initial operation. Following the initial biopsy, 21 patients received multi-agent neoadjuvant chemotherapy and wide resection, and eleven cases had metastases. The cytotoxic drugs used as preoperative chemotherapy were cis-diammine dichloroplatinum, Adriamycin, ifosphamide, and high-dose methotrexate. Eleven patients had metastases, and 5 years after the first medical examination, nine patients had died of their disease, and two patients died of intra- or postoperative complications (Table 1).

RNA isolation

1) Total RNA extraction from paraffin-embedded tissue sections

Five sections (each 10 µm thick) were prepared from paraffin-embedded tumor samples. We isolated RNA from these samples according to the method used by Stanta and Schneider [22]. After deparaffinization, RNA lysis buffer containing 2% SDS, 0.1 mM EDTA, 10 mM Tris-HCl, and proteinase K (20 mg/ml) was added. The mixture was incubated overnight at 60°C. After this incubation, RNA was extracted with 2 M sodium acetate, phenol and chloroform-isooamylalcohol (1:24). This mixture was centrifuged at 15,000 rpm for 20 min at 4°C. The aqueous supernatant was transferred to a new microtube and precipitated with an equal volume of isopropanol and addition of glycogen. After

Table 1. Patient information (1992 to 2000)

| Case | Age (yr) | Sex | Site       | Stage | Histology | Chemotherapy | Metastasis | Follow-up (months) | Outcome |
|------|---------|-----|------------|-------|-----------|--------------|------------|-------------------|---------|
| 1    | 17      | F   | Lt. Femur  | IIB   | Osteoblastic | +            | -          | 106               | CDF     |
| 2    | 22      | M   | Lt. Humerus| IIB   | Osteoblastic | +            | -          | 72                | CDF     |
| 3    | 9       | M   | Rt. Tibia  | IIB   | Osteoblastic | +            | -          | 61                | CDF     |
| 4    | 27      | M   | Lt. Tibia  | IIB   | Osteoblastic | +            | +          | 38                | DOD     |
| 5    | 20      | M   | Rt. 5th Rib| IIB   | Osteoblastic | +            | +          | 25                | DOD     |
| 6    | 55      | F   | 2, 3rd Lumbar| IIB | Osteoblastic | -            | +          | 35                | DOD     |
| 7    | 16      | F   | Rt. Tibia  | IIB   | Chondroblastic | +          | -          | 79                | CDF     |
| 8    | 12      | M   | Lt. Femur  | IIB   | Chondroblastic | +          | -          | 64                | CDF     |
| 9    | 20      | M   | Lt. Fibula | IIB   | Chondroblastic | +          | +          | 160               | NED     |
| 10   | 62      | F   | Lt. Femur  | IIB   | Chondroblastic | +          | -          | 73                | CDF     |
| 11   | 13      | M   | Lt. Femur  | IIB   | Fibroblastic | +            | +          | 55                | DOD     |
| 12   | 10      | M   | Lt. Tibia  | IIB   | Fibroblastic | +            | -          | 75                | CDF     |
| 13   | 13      | F   | Rt. Femur  | IIB   | Fibroblastic | +            | -          | 79                | CDF     |
| 14   | 41      | F   | Lt. Pelvis | IIB   | Fibroblastic | +            | /           | 2                 | DOO*    |
| 15   | 34      | M   | Lt. Tibia  | IIB   | Osteoblastic | +            | -          | 153               | CDF     |
| 16   | 17      | M   | Lt. Humerus| IIB   | Osteoblastic | +            | /           | 6                 | DOO**   |
| 17   | 12      | F   | Rt. Femur  | IIB   | Osteoblastic | +            | +          | 21                | DOD     |
| 18   | 13      | M   | Rt. Talus  | IIB   | Osteoblastic | +            | +          | 57                | DOD     |
| 19   | 8       | M   | Lt. Femur  | IIB   | Osteoblastic | +            | +          | 25                | DOD     |
| 20   | 54      | F   | Rt. Femur  | IIB   | Osteoblastic | +            | +          | 15                | DOD     |
| 21   | 13      | M   | Lt. Femur  | IIB   | Osteoblastic | +            | +          | 44                | DOD     |
| 22   | 60      | M   | 3rd Lumbar | IIB   | Osteoblastic | +            | +          | 62                | DOD     |

CDF, continuous disease free; NED, no evidence of disease; DOD, dead of disease; DOO, dead of other disease; *, intraoperative death; **, death due to a side effect of chemotherapy postoperatively.
the sample had been incubated at −80°C for at least 30 min, RNA was pelleted and washed in 70% ethanol and then 100% ethanol. The pellet was dried and resuspended in TE buffer.

2) RNA extraction from NOS-1

Total RNA was extracted from the osteosarcoma cell line NOS-1 with TRIZol reagent (Gibco BAL) by the acid-guanidium-phenol chloroform method.

Quantification of RNA

The total RNA quantity was determined by ultraviolet (UV) spectrophotometry using Gene Spec III (Hitachi). We adjusted the concentration of mRNA to 0.5 g/ml.

Reverse transcription-polymerase chain reaction (RT-PCR)

RNA was reverse transcribed to cDNA using a Takara RNA PCR kit (AMV) Version 3.0 (Takara, Otsu, Japan) with oligo (dT) as a primer. RT reactions were carried out at 42°C for 30 min, followed by annealing at 99°C for 5 min and finally holding at 4°C. PCR amplifications were performed on a Mastercycler (Eppendorf, Westbury, NY, USA).

To determine the saturation phase of RT-PCR amplification, we started with cycle titrations for survivin. Reactions were stopped after 10, 20, 25, 30, 35, 40, 45, 50 and 60 cycles. The PCR cycle number determined for survivin was 35, hence the saturation phase was not reached.

We used human glyceraldehyde-3-phosphate dehydrogenase (h-GAPDH) as an internal marker and NOS-1 as a positive control. In paraffin-embedded tissues, PCR products larger than 200 bp were undetectable because of nucleic acid degradation. We therefore designed primers with less than 200 bp, and primer pairs for survivin mRNA were as follows. The sequence of the forward primer for survivin was 5'-TGCCCCGACGTTGCC-3', and the sequence of the reverse primer for survivin was 5'-CAGTTCTTGAATGTA-GAGATGCGGT-3'.

Analysis and quantities of PCR products

PCR products were electrophoresed through 12% polyacrylamide gel, because of difficulty obtaining short PCR products from paraffin-embedded tissues when using agarose gel. We used Scion Image (Scion Corp., Frederick, MD) to accurately determine band densities. For each sample, we determined the survivin/GAPDH mRNA ratio.

Statistical analysis

All statistical analyses were performed using the SPSS 11.0J software package for Windows (SPSS Inc., Chicago, IL). The differences of survivin mRNA expression with various clinicopathological parameters were analyzed using either the Mann-Whitney U test or the Kruskal-Wallis test. Survival time was calculated as the date of resection until date of death or date of the latest follow-up. Survival curves were plotted by the Kaplan-Meier method; statistical differences were analyzed using the log-rank test. A probability value less than 0.05 was considered to indicate a statistically significant difference.

III. Results

RT-PCR was performed to determine the expressions of survivin mRNA in normal tissues, the osteosarcoma cell line NOS-1, and clinical samples from osteosarcoma patients. Survivin mRNA expression was detected in all osteosarcoma samples but none of the normal tissues. We used pre-saturation phase PCR amplification cycle numbers for survivin and GAPDH. This made densitometric evaluation and comparison of mRNA levels among tissue samples feasible.

Expression of survivin mRNA in normal tissues, NOS-1 and clinical samples

No survivin mRNA was detected in normal bone, fat or muscle tissues, and survivin mRNA expression was detected in NOS-1 (Fig. 1). Survivin mRNA was detectable in all osteosarcoma samples, and levels of survivin mRNA were 0.83±0.25 in initial biopsy samples (Fig. 2). Results are presented in Table 2.

Correlations among metastatic status, 5 year survival and levels of survivin mRNA expression

In patients with metastases, as compared to those without metastases, survivin mRNA levels were higher in both initial biopsy samples (Fig. 2). Among patients who died within 5 years of being diagnosed with osteosarcoma, survivin mRNA levels were also high in both initial biopsy
samples. However, there were no statistically significant relationships with other clinicopathological parameters (stage, histological type, age, sex and tumor site) (Table 3). Further, the comparison of stage IIB and IIIB cannot be said to be entirely reliable due to the small number of patients involved in IIB.

### Table 2. Levels of survivin mRNA expression

| Case | Survivin/GAPDH |
|------|----------------|
| 1    | 0.66           |
| 2    | 0.73           |
| 3    | 0.77           |
| 4    | 1.12           |
| 5    | 0.91           |
| 6    | 0.93           |
| 7    | 0.73           |
| 8    | 0.64           |
| 9    | 0.66           |
| 10   | 0.56           |
| 11   | 1.34           |
| 12   | 0.75           |
| 13   | 0.6            |
| 14   | 0.69           |
| 15   | 0.51           |
| 16   | 1.03           |
| 17   | 1.4            |
| 18   | 1.14           |
| 19   | 0.95           |
| 20   | 0.81           |
| 21   | 0.69           |
| 22   | 0.54           |

### Table 3. Comparison of survivin mRNA levels according to clinicopathological parameters

| Variables                                      | No. of patients | p-value |
|------------------------------------------------|-----------------|---------|
| Stage                                          |                 |         |
| IIB vs IIIB                                    | 20 vs 2         | 0.17    |
| Histological type                              |                 |         |
| osteoblastic vs chondroblastic vs fibroblastic type | 14 vs 4 vs 4   | 0.18    |
| Metastasis                                     |                 |         |
| Meta vs Non-meta                               | 11 vs 9         | <0.01   |
| Age                                            |                 |         |
| ≤20 years vs >20 years                         | 14 vs 8         | 0.24    |
| Sex                                            |                 |         |
| Male vs Female                                 | 14 vs 8         | 0.62    |
| Tumor development area                         |                 |         |
| upper extremity vs lower extremity vs others   | 2 vs 14 vs 6    | 0.58    |
| 5 year survival alive vs dead                  | 11 vs 9         | <0.01   |

Differences were analyzed using either the Mann-Whitney U test or the Kruskal-Wallis test. Probability values less than 0.05 were considered to indicate a statistically significant difference.

**IV. Discussion**

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. It is a highly aggressive neoplasm typically composed of spindle cells producing osteoids. The prognosis for patients with osteosarcoma has typically been very poor, and clinically has been determined postoperatively by the response to chemotherapy and, in the past, by tumor size. These have long been the only useful prognostic factors for osteosarcoma patients.

Recently, several studies have shown survivin mRNA expression to be detectable in various human cancers, and that there are correlations between the expression levels of this gene and prognosis [12–17, 20, 21, 25, 27]. The only report on survivin expression in osteosarcoma used immunohistochemistry. Survivin expression is also reportedly a useful prognostic marker in osteosarcoma, and patients showing survivin expression could potentially benefit from optimal selection of neoadjuvant chemotherapy [25]. In this study, we demonstrated, for the first time, expressions of survivin mRNA in paraffin-embedded tumor tissues, obtained by initial biopsy, using competitive RT-PCR.

Moreover, survivin has been regarded as a novel member of the IAP family. Survivin is structurally unique among mammalian IAPs, containing only a single BIR and lacking a carboxy terminal RING finger domain. Survivin was shown to inhibit processing of procaspase-3 and procaspase-7 and to specifically bind both active caspases in vitro [5,
Survivin Expression in Osteosarcoma

99

24]. Remarkably, caspase-3 plays a key role in promoting the apoptosis signal [6].

It has recently become possible to isolate RNA from formalin-fixed paraffin-embedded tissue and to perform RT-PCR using this RNA [10, 22]. In fact, several reports have described gene analyses using RNA extracted from paraffin-embedded tissues from retinoblastoma [22], Ewing’s sarcoma [2, 18], small round-cell tumor [7], synovial sarcoma [26], liposarcoma [11], rhabdomyosarcoma [8] and colon cancer [23]. Abrahamson et al. [1] described quantitative analysis of mRNA in archived and routine diagnostic tissues as being possible for melanoma.

We analyzed survivin mRNA expression levels using the RT-PCR method. As to osteosarcoma, high expression of survivin mRNA in initial biopsy samples was especially common in cases with metastases. In the initial biopsy samples from patients who died within 5 years, levels of expression of this gene were high. Moreover, the 5 year survival rate was much lower in the high expression than in the low expression group (Fig. 3). Our results do not conflict with those of previous studies [12–17, 20, 21, 25, 27]. In spite of their small size, osteosarcoma in patients with high survivin mRNA expression may be rapidly growing and metastasizing with increased resistance to chemotherapeutic regimens.

We conclude that survivin levels in initial biopsy samples are useful prognostic indicators, that can be used not only to determine whether this gene is expressed or not, but also the level of expression, using paraffin-embedded tissues. Our findings raise the possibility of performing retrospective molecular profiling, at the mRNA level, of archived tissues employing a routine diagnostic technique.

V. Acknowledgments

We thank Dr. Christine A. Towle (Orthopaedic Laboratory of Massachusetts General Hospital) for her help in preparing the manuscript, and Drs. Tetsuo Hotta and Teiichi Motoyama (Yamagata University School of Medicine) for providing the cell line (NOS-1). This work was supported in part by the Academic Frontier Project for Private Universities, a matching fund subsidy from MEXT (Ministry of Education, Culture, Sports Science and Technology) 2002–2006.

VI. References

1. Abrahamson, H. N., Steiniche, T., Nexo, E., Hamilton-Dutoit, S. J. and Sorensen, B. S. (2003) Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J. Mol. Diagn. 5; 34–41.

2. Adams, V., Hany, M. A., Schmid, M., Hassam, S., Briner, J. and Niggli, F. K. (1996) Detection of t(11;22)(q24;q12) translocation breakpoint in paraffin-embedded tissue of the Ewing’s sarcoma family by nested reverse transcription-polymerase chain reaction. Diagn. Mol. Pathol. 5; 107–113.

3. Ambrosini, G., Adida, C. and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3; 917–921.

4. Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Fliege, S., Helmke, K., Kote, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., Zoubeik, A., Jurgens, H. and Winkler, K. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20; 776–790.

5. Chiou, S. K., Jones, M. K. and Tamawski, A. S. (2003) Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med. Sci. Monit. 9; P125–29.

6. Cohen, G. M. (1997) Caspases: the executioners of apoptosis. Biochem. J. 326; 1–16.

7. Dorsey, B. V., Benjamin, L. E., Rauscher F., 3rd., Klencke, B., Venook, A. P., Warren, R. S. and Weidner, N. (1996) Intrabdominal desmoplastic small round-cell tumor: expansion of the pathologic profile. Mod. Pathol. 9; 703–709.

8. Edwards, R. H., Chatten, J., Xiong, Q. B. and Barr, F. G. (1997) Detection of gene fusions in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction assay of archival samples. Diagn. Mol. Pathol. 6; 91–97.

9. Enneking, W. F., Spanier, S. S. and Goodman, M. A. (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. Relat. Res. 153; 106–120.

10. Finke, J., Fritzen, R., Temes, P., Lange, W. and Dolken, G. (1993) An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 14; 448–453.

11. Hisaoka, M., Tsuji, S., Morimitsu, Y., Hashimoto, H., Shimajiri, S., Komiya, S. and Ushijima, M. (1998) Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Diagn. Mol. Pathol. 7; 96–101.

12. Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Iogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y. and Nakagawara, A. (2000) High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19; 617–623.

13. Kami, K., Doi, R., Koizumi, M., Toyoda, E., Mori, T., Ito, D., Fujimoto, K., Wada, M., Miyatake, S. and Imamura, M. (2004) Survivin expression in a prognostic marker in pancreatic cancer patients. Surgery 136; 443–448.

14. Kappler, M., Kohler, T., Kampf, C., Diestelkotter, P., Wurl, P., Schmitz, M., Bartel, F., Lautenschlager, C., Rieber, E. P., Schmidt, H., Bache, M., Taubert, H. and Meye, A. (2001) Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer 95; 360–363.

15. Meng, H., Lu, C. D., Sun, Y. L., Dai, D. J., Lee, S. W. and Tanigawa, N. (2004) Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J. Gastroenterol. 10; 3245–3250.

16. Miyachi, K., Sasaki, K., Onodera, S., Taguchi, T., Nagamachi, M., Kaneko, H. and Sunagawa, M. (2003) Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 6; 217–224.

17. Monzo, M., Rosell, R., Felip, E., Astudillo, J., Sanchez, J. J., Maestre, J., Martin, C., Font, A., Barnadas, A. and Abad, A. (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17; 2100–2104.

18. Park, Y. K., Chi, S. G., Park, H. R., Yang, M. H. and Unni, K. K. (1998) Detection of t(11;22)(q24;q12) translocation of Ewing’s sarcoma in paraffin embedded tissue by nested reverse transcription-polymerase chain reaction. J. Korean Med. Sci. 13; 395–399.
19. Rosen, G. and Nirenberg, A. (1985) Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). *Prog. Clin. Biol. Res.* 201; 39–51.

20. Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F. and Guillou, P. J. (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. *Gut* 46; 645–650.

21. Span, P. N., Sweep, F. C., Wijgerinck, E. T., Tjan-Heijnen, V. C., Manders, P., Beex, L. V. and de Kok, J. B. (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. *Clin. Chem.* 50; 1986–1993.

22. Stanta, G. and Schneider, C. (1991) RNA extracted from paraffin-embedded human tissues is amenable to analysis by PCR amplification. *Biotechniques* 11; 304, 306, 308.

23. Takenaka, M., Immamura, T., Nojima, T. and Takegami, T. (2001) Extraction of RNA from paraffin embedded tissues and analysis of p53 gene expression in colonic cancer. *Rinsho Byori* 49; 278–282.

24. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. *Cancer Res.* 58; 5315–5320.

25. Trieb, K., Lehner, R., Stulnig, T., Sulzbacher, I. and Shroyer, K. R. (2003) Survivin expression in human osteosarcoma is a marker for survival. *Eur. J. Surg. Oncol.* 29; 379–382.

26. Tsuji, S., Hisaoka, M., Morimitsu, Y., Hashimoto, H., Shimajiri, S., Komiyi, S., Ushijima, M. and Nakamura, T. (1998) Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. *Am. J. Pathol.* 153; 1807–1812.

27. Wang, H., Xi, X., Kong, X., Huang, G. and Ge, G. (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. *J. Cancer Res. Clin. Oncol.* 130; 487–490.